DTIL Stock Summary and Trading Ideas (Precision Biosciences | NASDAQ:DTIL)

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Precision Biosciences trades on the NASDAQ stock market under the symbol DTIL.

As of April 18, 2024, DTIL stock price declined to $10.72 with 67,679 million shares trading.

DTIL has a beta of 2.54, meaning it tends to be more sensitive to market movements. DTIL has a correlation of 0.17 to the broad based SPY ETF.

DTIL has a market cap of $70.37 million. This is considered a Micro Cap stock.

Last quarter Precision Biosciences reported $7 million in Revenue and -$3.35 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$1.30.

In the last 3 years, DTIL stock traded as high as $431.40 and as low as $8.25.

The top ETF exchange traded funds that DTIL belongs to (by Net Assets): VTI, VXF, AVSC.

DTIL has underperformed the market in the last year with a price return of -56.7% while the SPY ETF gained +22.3%. DTIL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.4% and -30.6%, respectively, while the SPY returned +6.1% and -3.8%, respectively.

DTIL support price is $10.87 and resistance is $12.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DTIL stock will trade within this expected range on the day.